Breast cancer diagnostics market seen reaching $7.28 billion by 2030

The breast cancer diagnostics market is projected to rise from $5.42 billion in 2026 to $7.28 billion by 2030, according to The Business Research Company. Growth is being driven by government screening funding, broader use of biomarker and molecular tests, and faster adoption of AI-assisted imaging.

Why it matters: - Breast cancer diagnostics support earlier detection, staging and treatment selection, which can improve patient outcomes. - The market’s expected growth signals continued spending on screening, imaging, biopsy tools and precision testing. - Public funding and expanded screening programs are likely to shape access to diagnosis across major markets.

What happened: - The Business Research Company issued a Breast Cancer Diagnostics Market Report 2026 on July 29, 2026. - The report forecasts the market will grow from $5.42 billion in 2026 to $7.28 billion by 2030. - The report puts the market on a 7.7% compound annual growth rate over the forecast period. - The company also says the market was worth $5 billion in 2025. - Download a free sample of the report. - View the full report.

The details: - The report ties near-term growth to rising breast cancer cases, greater awareness of early screening, expanded diagnostic imaging, broader access to biomarker-based tests, and safer biopsy procedures. - Future growth is expected to come from precision oncology diagnostics, AI-powered diagnostic platforms, minimally invasive testing, population screening programs and molecular diagnostics. - The report highlights wider use of AI-assisted imaging, genomic and molecular testing, liquid biopsy techniques, advanced non-ionizing imaging technologies and more personalized cancer diagnosis. - Breast cancer diagnostics include tests and procedures used to detect breast cancer, confirm disease, determine stage and guide treatment. - In 2025, North America held the largest share of the market. - Asia-Pacific ranked second and is expected to post strong growth. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - Government policy is emerging as a material market driver, not just clinical demand. - The Australia example shows how national budgets can directly support screening capacity and diagnostic uptake. - The strong emphasis on AI, liquid biopsy and molecular testing suggests a shift toward earlier and more personalized diagnosis.

What's next: - The market is expected to continue expanding through 2030 as screening programs widen and diagnostic technologies advance. - Investment in AI-enabled imaging and precision diagnostics is likely to remain a core theme in market development. - The company’s report adds updated graphics, forecasting dashboards and analysis tools aimed at tracking those shifts.